Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
The crustacean DNA virus tegument protein vp26 binds to snap29 to inhibit snare complex assembly and autophagic degradation
What May Be Driving Skin Aging at the Cellular Level Visible changes in your skin often begin beneath the surface
Reduced Expression of 14-3-3 Gamma in Uterine Leiomyoma as Identified by Proteomics
For glucose uptake and GLUT-1 surface detection splenocytes were washed with glucose-free RPMI medium (Lonza BE12-752F)
US$ 26.55
US$ 26.61
US$ 21.43
